Citi Research issued a research report expecting SINO BIOPHARM (01177.HK) +0.030 (+1.087%) Short selling $19.73M; Ratio 21.373% to post intact 1H24 results, with earnings expected to grow by about 10% YoY due to strong sales growth of biosimilar and innovative drugs.
Higher visibility is expected in the Company's 2H24 results on increased sales of biosimilar, G-CSF and Cataplasms.
Citi Research opened an upside 30-day catalyst watch on SINO BIOPHARM, with a target price of $6.8 and rating at Buy.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-07-25 16:25.)
AAStocks Financial News
Byte refutes rumors of speculation on A-share Doubao concept stocks
How to develop a low-altitude economy
Doubao concept surges, IPO economy booms
5G enters the "second half", which stocks are the best to buy
Check whenever you want
WikiStock APP